Statistical issues in bioequivalance

被引:23
作者
Senn, S [1 ]
机构
[1] UCL, Dept Epidemiol & Publ Hlth, Dept Stat Sci, London WC1E 6BT, England
关键词
D O I
10.1002/sim.743
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
There has been much work recently on individual bioequivalence and the topic has attracted considerable controversy. Some previous controversies regarding average bioequivalence are examined. It is argued that a contributory factor in these controversies may have been confusion over the purpose of bioequivalence trials. It is concluded that this purpose needs further clarification before guidelines for individual bioequivalence can be established and indeed that such guidelines may turn out to be unnecessary. Copyright (C) 2001 John Wiley & Sons, Ltd.
引用
收藏
页码:2785 / 2799
页数:15
相关论文
共 28 条
[1]   FORMOTEROL - PHARMACOLOGY, MOLECULAR-BASIS OF AGONISM, AND MECHANISM OF LONG-DURATION OF A HIGHLY POTENT AND SELECTIVE BETA(2)-ADRENOCEPTOR AGONIST BRONCHODILATOR [J].
ANDERSON, GP .
LIFE SCIENCES, 1993, 52 (26) :2145-2160
[2]   A NEW PROCEDURE FOR TESTING EQUIVALENCE IN COMPARATIVE BIOAVAILABILITY AND OTHER CLINICAL-TRIALS [J].
ANDERSON, S ;
HAUCK, WW .
COMMUNICATIONS IN STATISTICS-THEORY AND METHODS, 1983, 12 (23) :2663-2692
[3]   CONSIDERATION OF INDIVIDUAL BIOEQUIVALENCE [J].
ANDERSON, S ;
HAUCK, WW .
JOURNAL OF PHARMACOKINETICS AND BIOPHARMACEUTICS, 1990, 18 (03) :259-273
[4]  
ARMITAGE P, 1981, BIOMETRICS, V37, P593
[5]  
Berger RL, 1996, STAT SCI, V11, P283
[6]  
Brown LD, 1997, ANN STAT, V25, P2345
[7]  
*CTR DRUG EV RES, 1999, GUID IND AV POP IND
[8]  
Grieve A P, 1998, J Biopharm Stat, V8, P377, DOI 10.1080/10543409808835247
[9]  
Hauck WW, 1996, INT J CLIN PHARM TH, V34, P535
[10]  
HAUSCHKE D, 1997, CROSS OVER CLIN TRIA, P27